ImmuPharma recruits patients for Phase III study of Lupuzor

ImmuPharma has completed patients recruitment regarding pivotal Phase III clinical trial of Lupuzor, its lead programme for the potential breakthrough compound for Lupus, the life threatening auto-immune disease.

Lupuzor has been given the ‘Gold Standard’ approval by the US FDA for its Phase III programme with a Sprecial Protocol Assessment (SPA) and fast track designation.

Commenting on this announcement, Tim McCarthy, Chairman of ImmuPharma said: “This is a major milestone for ImmuPharma confirming the completion of patient recruitment into this study. We look forward to providing further updates as and when possible on this pivotal Phase III trial as it progresses through 2017.”

Lupus (or Systemic Lupus Erythematosus) is a chronic, potentially life-threatening autoimmune disease. An estimated 1.4 million people are diagnosed in the 7 major world markets (the USA, Japan, Germany, France, Spain, the UK and Italy). Lupus is an inflammatory disease, which attacks multiple organs such as the skin, joints, kidneys, blood cells, heart and lungs. There is currently no cure.